Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Richert

Showing results (31-40 of 94) with videos related to

Pageof 10
Sort By:
Frontiers in Immunology|May 21, 2019
Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected IndividualsRodolphe Thiébaut, Boris P Hejblum, Hakim Hocini, et al.
Frontiers in Immunology|December 18, 2020
Distinct Signatures in the Receptor Repertoire Discriminate CD56bright and CD56dim Natural Killer CellsVera Schwane, Van Hung Huynh-Tran, Sarah Vollmers, et al.
The Journal of Clinical Investigation|March 4, 2020
Tissue-resident T cell-derived cytokines eliminate herpes simplex virus-2-infected cellsPavitra Roychoudhury, David A Swan, Elizabeth Duke, et al.
The Lancet. HIV|May 4, 2019
Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventionsCecilia L Moore, Wolfgang Stöhr, Angela M Crook, et al.
The Lancet. Infectious Diseases|July 21, 2020
Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation studyMaja Jahnmatz, Laura Richert, Nabil Al-Tawil, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 27, 2018
Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 TrialAdriana Ammassari, Wolfgang Stöhr, Andrea Antinori, et al.
The Journal of Infectious Diseases|July 16, 2024
Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 TrialChristine Lacabaratz, Mélany Durand, Aurélie Wiedemann, et al.
Journal of Reproductive Immunology|June 13, 2020
In-depth characterization of monocyte subsets during the course of healthy pregnancyCaroline Pflitsch, Cai Niklaas Feldmann, Laura Richert, et al.
Trials|July 13, 2019
Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic contextEdouard Lhomme, Camara Modet, Augustin Augier, et al.
Journal of Community Genetics|March 29, 2019
Evaluation of the template letter regarding the disclosure of genetic information within the family in FranceCécile Zordan, Laetitia Monteil, Emmanuelle Haquet, et al.
Pageof 10

Showing results (31-40 of 94) with videos related to

Sort By:
Pageof 10
Frontiers in Immunology|May 21, 2019
Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected IndividualsRodolphe Thiébaut, Boris P Hejblum, Hakim Hocini, et al.
Frontiers in Immunology|December 18, 2020
Distinct Signatures in the Receptor Repertoire Discriminate CD56bright and CD56dim Natural Killer CellsVera Schwane, Van Hung Huynh-Tran, Sarah Vollmers, et al.
The Journal of Clinical Investigation|March 4, 2020
Tissue-resident T cell-derived cytokines eliminate herpes simplex virus-2-infected cellsPavitra Roychoudhury, David A Swan, Elizabeth Duke, et al.
The Lancet. HIV|May 4, 2019
Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventionsCecilia L Moore, Wolfgang Stöhr, Angela M Crook, et al.
The Lancet. Infectious Diseases|July 21, 2020
Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation studyMaja Jahnmatz, Laura Richert, Nabil Al-Tawil, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 27, 2018
Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 TrialAdriana Ammassari, Wolfgang Stöhr, Andrea Antinori, et al.
The Journal of Infectious Diseases|July 16, 2024
Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 TrialChristine Lacabaratz, Mélany Durand, Aurélie Wiedemann, et al.
Journal of Reproductive Immunology|June 13, 2020
In-depth characterization of monocyte subsets during the course of healthy pregnancyCaroline Pflitsch, Cai Niklaas Feldmann, Laura Richert, et al.
Trials|July 13, 2019
Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic contextEdouard Lhomme, Camara Modet, Augustin Augier, et al.
Journal of Community Genetics|March 29, 2019
Evaluation of the template letter regarding the disclosure of genetic information within the family in FranceCécile Zordan, Laetitia Monteil, Emmanuelle Haquet, et al.
Pageof 10